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O-Linked GlcNAc transferase (OGT) possesses dual glycosyl-
transferase–protease activities.OGT thereby stably glycosylates
serines and threonines of numerous proteins and, via a transient
glutamate glycosylation, cleaves a single known substrate—the
so-called HCF-1PRO repeat of the transcriptional co-regulator
host-cell factor 1 (HCF-1). Here, we probed the relationship
between these distinct glycosylation and proteolytic activities.
For proteolysis, the HCF-1PRO repeat possesses an important
extended threonine-rich region that is tightly bound by the
OGT tetratricopeptide-repeat (TPR) region. We report that
linkage of this HCF-1PRO-repeat, threonine-rich region to het-
erologous substrate sequences also potentiates robust serine
glycosylation with the otherwise poor Rp-S-UDP-GlcNAc
diastereomer phosphorothioate and UDP-5S-GlcNAc OGT co-
substrates. Furthermore, it potentiated proteolysis of a non-
HCF-1PRO-repeat cleavage sequence, provided it contained an
appropriately positioned glutamate residue. Using serine- or
glutamate-containing HCF-1PRO-repeat sequences, we show
that proposed OGT-based or UDP-GlcNAc–based serine-
acceptor residue activation mechanisms can be circumvented
independently, but not when disrupted together. In contrast,
disruption of both proposed activation mechanisms even in
combination did not inhibit OGT-mediated proteolysis. These
results reveal a multiplicity of OGT glycosylation strategies,
some leading to proteolysis, which could be targets of alterna-
tive molecular regulatory strategies.
GlcNAc transferase (OGT)4 has an unusual dual glycosyl-
transferase–protease activity (1). It is implicated in numerous
intracellular signaling pathways throughO-linked addition of a
single GlcNAc moiety to acceptor serines or threonines in tar-
get proteins; these modifications are reversible by the enzy-
matic activity of O-GlcNAcase. In addition to this “canonical”
serine-threonine glycosyltransferase activity,OGThas a special
protease activity in which it cleaves a very specific substrate—
the 26-amino acid HCF-1PRO repeat of the cell proliferation
host-cell factor HCF-1—at a key glutamate residue at position
10 (Glu-10) of the HCF-1PRO repeat (1, 2).
The proteolytic activity results froma second “noncanonical”
glycosyltransferase activity—to date specific to the HCF-1PRO
repeat—by which OGT O-GlcNAcylates the Glu-10 residue,
leading to autoproteolysis (3). Curiously, glycosylation of a glu-
tamate residue in a non-OGT–related context is sufficient for
spontaneous backbone cleavage (4). Thus, the HCF-1PRO
repeat appears to be a very specific OGT cleavage substrate
because it is able to induce OGT toO-GlcNAcylate the Glu-10
residue. Indeed, the HCF-1PRO repeat interacts intimately with
OGT across much of its length, favorably positioning the
Glu-10 residue adjacent to the UDP-GlcNAc for glycosylation
(2). The close relationship of glutamate and serine/threonine
glycosylation is substantiated by the finding that a Glu-to-Ser
substitution (E10S) changes the HCF-1PRO repeat from a gluta-
mate-directed cleavage substrate into a serine-directed stable
glycosylation substrate (2).
Here, we examine the glycosylation and cleavage activities of
OGT on HCF-1PRO repeat–related and –nonrelated substrates
and find that position 10 of the HCF-1PRO repeat confers spe-
cial enzymatic OGT glycosylation properties on substrates
leading to different outcomes: canonical serine glycosylation or
noncanonical glutamate-induced proteolysis.
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Results
To study the canonical serine and threonine glycosylation
and noncanonical glycosyl glutamate–induced cleavage activi-
ties of OGT, we used human casein kinase 2 (CK2) and HCF-
1PRO-repeat substrates, respectively, using both native and
recombinant proteins aswell as synthetic peptides. Protein sub-
strates were used for immunoblot analysis with both GlcNAc
and protein substrate–specific antibodies, whereas peptides
were used forMS analysis. Additionally, to assessUDP-GlcNAc
co-substrate requirements, we also used three different oxygen-
to-sulfur–substituted UDP-GlcNAc co-substrates—the two
Rp-S-UDP-GlcNAc and Sp-S-UDP-GlcNAc diastereomer
phosphorothioate analogs (5) and the pyranose ring–modified
UDP-5S-GlcNAc (6).
The HCF-1PRO-repeat E10S substrate displays relaxed
UDP-GlcNAc co-substrate requirements
Fig. 1 shows (i) the general structure of HCF-1 (A) and (ii) a
surface representation of the OGT-HCF-1PRO-repeat complex
with the OGT catalytic domain in tan and the 13.5 tetratrico-
peptide-repeat (TPR) domain in gray, together with the HCF-
1PRO-repeat 2 sequence (orange) with regions identified (B).
HumanHCF-1 contains six cleavable HCF-1PRO repeats (HCF-
1PRO repeats 1–6) (7, 8). The HCF-1PRO repeat–based protein
substrates used here were variants of the previously described
HCF3R bacterial expression construct (2), which contains
HCF-1PRO repeats 1–3 (Fig. 1A). To retain only one active
HCF-1PRO repeat, HCF-1PRO repeats 1 and 3 were inactivated
by an E10A glutamate-to-alanine substitution, creating the so-
called HCF3R-AEA substrate. For HCF-1PRO-repeat E10S O-
GlcNAcylation, we prepared the related noncleavable HCF3R-
ASA construct (see Table S2 for sequences). As shown in Fig.
2A, like the canonical CK2 OGT substrate, HCF3R-ASA is also
an effective OGTO-GlcNAcylation substrate (compare lanes 1
and 2 with lanes 5 and 6).
Consistent with previous results using other substrates (5,
9), CK2 substrate O-GlcNAcylation by OGT was main-
tained, albeit with reduced efficiency, when Sp-S-UDP-
GlcNAc was utilized, whereas no O-GlcNAcylated CK2 pro-
tein was observed in the presence of Rp-S-UDP-GlcNAc
(Fig. 2A, compare lanes 3 and 4). In strong contrast, reac-
tions using the HCF3R-ASA substrate and either of the two
UDP-GlcNAc diastereomers as co-substrate yielded similar
robust O-GlcNAcylation activities (Fig. 2A, lanes 7 and 8).
The strong HCF3R-ASA glycosylation with Rp-S-UDP-
GlcNAc was unexpected.
Figure 1. HumanHCF-1, OGT, andHCF-1PRO repeat. A, domain representation of humanHCF-1. The centrally located HCF-1PRO repeats are shown as yellow
triangles. The HCF3R substrate contains HCF-1PRO repeats 1–3. B, depiction of HCF-1PRO repeat 2 and OGT based on crystal structures 4N3B and 1W3B. The
HCF-1PRO repeat (orange) interactswith theOGT catalytic domain (tan) aswell as theOGT TPRdomain (gray). TPR residues 313–463 are transparent to show the
internal occupancy of the HCF-1PRO-repeat 2 Thr-rich region. The amino acid sequence of HCF-1PRO repeat 2, further classified into cleavage (residues 7–10),
linker (residues 11–13), and Thr-rich (residues 14–24) regions, is shown below. E (red), site of proteolytic cleavage.
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To study this unexpected activity further, we adopted a pep-
tide substrate coupledwith anHPLC-tandemMS (LC-MS/MS)
approach. By using peptide substrates and MS, we could easily
manipulate well-defined peptide sequences as well as compare
the number and site(s) of glycosylation in the resulting reaction
products. As CK2 and HCF-1PRO-repeat representatives,
we used the previously described CK2-derived peptide
NH2-KKKYPGGSTPVSSANMM-COOH (10) (serine acceptor
underlined) and an HCF-1PRO repeat 2–derived E10S peptide
NH2-VRVCSNPPCSTHETGTTNTATTATSN-COOH (E10S
position underlined) as OGT substrates. Consistent with the
immunoblotting results in Fig. 2A, we observed O-GlcNAcylation
of the CK2 peptide by OGT with UDP-GlcNAc and with
Sp-S-UDP-GlcNAc, albeit at reduced levels, whereas
Rp-S-UDP-GlcNAc was essentially inactive (Fig. 2B). Also
consistent with the immunoblotting results, we observed
O-GlcNAcylation of the E10S peptide by OGT with any of the
three UDP-GlcNAc and Sp- and Rp-S-UDP-GlcNAc co-sub-
strates (Fig. 2C). A time course showed that the two diaste-
reomer UDP-GlcNAc substrates had parallel rates of glycosyl-
ation (Fig. S1).
To verify the precise status of E10S peptide glycosylation,
we performed electron transfer dissociation analysis of the
Rp-S-UDP-GlcNAc E10S peptide product. As shown in Fig.
2D, the product is uniquely glycosylated at the E10S position.
Thus, the E10S peptide relaxes the molecular constraints on
UDP-GlcNAc–related co-substrates for OGT glycosyltrans-
ferase activity.
The HCF-1PRO-repeat threonine-rich region is responsible for
the relaxed E10S peptide UDP-GlcNAc co-substrate
requirements
To identify the properties of the E10S peptide responsible
for its unusual relaxed UDP-GlcNAc co-substrate require-
ments, we compared the co-substrate requirements of the
CK2 and E10S peptides by preparing two chimeric (Ch) pep-
tides. As shown in Fig. 1B, the HCF-1PRO repeat has been
divided into three regions: cleavage (PPCE) and threonine-
rich (TGTTNTATTAT) regions held together by a flexible
three amino acid (THE) linker segment (9). In the OGT-
bound WT HCF-1PRO-repeat substrate, the Glu-10–
containing cleavage region lies beside the UDP-GlcNAc co-
substrate in the OGT catalytic domain, and the threonine-
rich region binds the TPR domain anchoring the HCF-1PRO
repeat in OGT (2). In the E10S HCF-1PRO-repeat substrate,
theWTHCF-1PRO-repeat cleavage region is converted into a
“glycosylation region.”
As shown in Fig. 3A, the first chimeric peptide, called Ch10,
replaced the N-terminal E10S HCF-1PRO-repeat glycosylation
region (residues 1–10) with the corresponding CK2 peptide
sequence (residues 1–12). The second, called Ch13, replaced
both the glycosylation region and the THE linker (residues
1–13) with the corresponding CK2 peptide sequence (residues
1–15). These two chimeric peptides displayed co-substrate
glycosylation selectivity similar to the HCF-1PRO-repeat E10S
peptide, being also readily active with the Rp-S-UDP-GlcNAc
co-substrate. Thus, neither the E10S HCF-1PRO-repeat gly-
cosylation region nor the THE linker is essential for its relaxed
co-substrate requirements.
These results led us to focus on the importance of the threo-
nine-rich region, for which we created three Ch13 peptide–
based mutants, called Ch13-T14A, Ch13-T14Y and Ch13-
T(17–22)A. In Ch13-T14A and Ch13-T14Y, we replaced
position Thr-14, the first residue of the threonine-rich region
(see Fig. 3A) and a residue critical for HCF-1PRO-repeat cleav-
age (11), either conservatively with alanine (Ch13-T14A) or
radically with tyrosine (Ch13-T14Y). In Ch13-T(17–22)A, we
replaced four conserved threonine residues with alanine, a
mutation that severely disrupts OGT binding to the HCF-1PRO
repeat (1).
Fig. 3C shows the results of peptide glycosylation assays with
UDP-GlcNAc and the Sp- and Rp-S-UDP-GlcNAc diaste-
reomers and these three threonine-rich region mutants. For
each peptide, the results are normalized to the activity of
UDP-GlcNAc for that peptide (see the legend to Fig. 3). The
Ch13 parental and Ch13-T14A and Ch13-T14Y mutant pep-
tides displayed similar activities with UDP-GlcNAc, whereas
the radical threonine-region Ch13-T(17–22)A mutant was
more than 10-fold less active. These results suggest that for
normal UDP-GlcNAc–induced glycosylation, the threonine
region is important because the Ch13-T(17–22)A mutant dis-
plays little activity and yet is not easily inactivated, as the Ch13-
T14A and Ch13-T14Y mutants remain active in these assays.
Indeed, the Ch13-T(17–22)A mutant showed activities similar
to the CK2 peptide: low overall UDP-GlcNAc utilization and
strong selectivity against the Rp-S-UDP-GlcNAc diaste-
reomer (compare Fig. 2B with Fig. 3C). In contrast, the Ch13-
T14A and Ch13-T14Y mutants have high UDP-GlcNAc utili-
zation and yet curiously display increasing discrimination
between the two Sp- and Rp-S-UDP-GlcNAc diastereomers,
whereas the Rp-S-UDP-GlcNAc diastereomer displays little if
any activity with the Ch13-T14Y mutant chimeric peptide.
Thus, the juxtaposition of theHCF-1PRO-repeat threonine-rich
region to the CK2 glycosylation site in the Ch13 chimeric pep-
tide has two distinct and separable effects on CK2 sequence
glycosylation: (i) it stimulates glycosylation and (ii) relaxes the
constraints on the use of the Rp-S-UDP-GlcNAc co-substrate
for OGT serine glycosylation.
Figure 2. The HCF-1PRO-repeat E10S substrate displays relaxed UDP-GlcNAc co-substrate requirements. A, in vitro substrate glycosylation assays were
performed using CK2 (lanes 1–4) and HCF3R-ASA proteins (lanes 5–8). Substrates were incubated without OGT (lanes 1 and 5) or with OGT and either
UDP-GlcNAc (lanes 2 and 6), Sp-S-UDP-GlcNAc (lanes 3 and 7), or Rp-S-UDP-GlcNAc (lanes 4 and 8). Substrate glycosylation was detected using RL2
anti-O-GlcNAc antibody. Anti-OGT, -CK2, and -His antibodies were used to detect OGT, CK2, and HCF3R-ASA proteins, respectively. B and C, in vitro peptide
glycosylation assays were performed using CK2 (B) and HCF-1PRO-repeat 2 E10S (C) peptides. Peptides were incubated with WT OGT and either UDP-GlcNAc,
Sp-S-UDP-GlcNAc, or Rp-S-UDP-GlcNAc, as indicated. Peptide glycosylation was detected using LC-MS. O-GlcNAcylation of the CK2 and E10S peptides in
different reactions was normalized to the O-GlcNAcylation activity with UDP-GlcNAc: 6.3  107 and 1.3  109, respectively. D, EThcD analysis of the
Rp-S-UDP-GlcNAc E10S glycopeptide product. Red and blue boxed products indicate the N-terminal c/b8 and c/b9, and C-terminal y/z17 and y/z16 ions,
respectively, that flank the glycosylated serine residue. Error bars, S.D.
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Molecular dynamic simulations of OGT/UDP-GlcNAc–peptide
substrate interactions
The aforementioned studies reveal a striking difference in
activity of the CK2 and HCF-1PRO-repeat E10S substrates and
that the CK2 substrate can be converted to an HCF-1PRO-re-
peat E10S-like substrate by fusion to the HCF-1PRO-repeat
threonine-rich region. Given this unusual activity spectrum,we
turned to computational methods to investigate how these dif-
ferent substrates might interact with OGT and UDP-GlcNAc.
As shown in Fig. 4C, we generated an initial structure of the
chimeric Ch13 peptide sequence by homology modeling, using
the X-ray diffraction–determined structures of the parental
Figure 3. The HCF-1PRO-repeat threonine-rich region is responsible for the relaxed E10S peptide UDP-GlcNAc co-substrate requirements. A, amino
acid sequences of native E10S and CK2 peptides as well as two chimeric peptides derived from CK2-E10S fusion (Ch10 and Ch13) are shown. The serine for
glycosylation (Glyco) is depicted in boldface type. The linker and Thr-rich region are indicated. B and C, in vitro peptide glycosylation assays were performed
using Ch10 and Ch13 chimeric peptides (B) and Ch13 T14A, T14Y, and T(17–22)A mutant peptides (C). Peptides were incubated with WT OGT and either
UDP-GlcNAc, Sp-S-UDP-GlcNAc, or Rp-S-UDP-GlcNAc, as indicated. Peptide glycosylation was detected using LC-MS. O-GlcNAcylation of the different
peptideswas in each case normalized toO-GlcNAcylation activitywithUDP-GlcNAc as follows: Ch10, 3.2 108; Ch13WT, 1.6 108; Ch13 T14A, 3.6 108; Ch13
T14Y, 2.0 108; and Ch13 T(17–22)A, 1.5 107. Error bars, S.D.
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Figure 4. Structural representations and MD simulations of OGT-UDP-GlcNAc–peptide complexes. A–C, representations of the structures of HCF-1PRO
repeat 2 (PDB code 4N3B) (A), CK2 (PDB code 4GYY) (B), and chimeric Ch13 peptide (homologymodel) (C) to the OGT (TPR domain (gray) and catalytic domain
(beige)). TPR domain residues that make critical backbone and side-chain interactions with the Thr-14 residue of Ch13 are shown in C. D, RMSDs of different
parts of the complexes from their initial structures observed during MD simulations. Based on structural superimposition of the backbone of the catalytic
domain of OGT (CD), the RMSD of the OGT catalytic domain, the OGT TPR domain, the UDP-GlcNAc sugar donor, and the central part of the bound peptide are
shown from left to right. The central part of the peptide includes three amino acids downstream and two upstreamof themodified residue. Simulated systems
are OGT bound to CK2 (black circle), HCF-1PRO-repeat 2 Glu-10 (red square), HCF-1PRO-repeat 2 E10S (blue triangle), and the chimeric Ch13 peptide (WT (purple
triangle) andT14Ymutant (turquoise triangle)). E, RMSDof the central six aminoacids of eachpeptide from their initial structure after structural superimposition
of the backbone of the TPR domain of OGT. Peptides that lack the HCF-1PRO-repeat Thr-rich region (CK2, black circle) show larger deviation movements than
those that possess the HCF-1PRO-repeat Thr-rich region (Glu-10, E10S, and Ch13). F, RMSD of the central six amino acids of each peptide from their initial
structure after structural superimposition of the backbone of the TPR domain of OGT. Peptides that lack the HCF-1PRO-repeat Thr-rich region (CK2, black circle)
show larger deviations than those that possess the HCF-1PRO-repeat Thr-rich region (Glu-10, E10S, and Ch13). Error bars, S.D.
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HCF-1PRO repeat and CK2 (Fig. 4, A and B) (2) as templates.
This approach yielded an OGT-bound Ch13 peptide structure
very similar to the CK2 crystal structure of Lazarus et al. (12)
(Fig. 4B) in the N terminus up to the serine-acceptor residue
(root mean square deviation (RMSD) 1.25 Å) and a structure
similar to the WT HCF-1PRO-repeat peptide in the threonine-
rich region (RMSD  0.90 Å). The SAN linker region of the
CK2 sequence adopts a conformation close to the linker region
of the HCF-1PRO repeat.
To test the relevance of the modeled OGT-bound chimeric
Ch13 peptide structure and to compare the molecular prop-
erties of the three OGT-bound peptides, we turned tomolec-
ular dynamic simulations as shown in Fig. 4 (D–F). Fig. 4D
shows the relative movements of the TPR and catalytic
domains as well as of UDP-GlcNAc and of the peptide gly-
cosylation region (3 to 2 of the serine acceptor at posi-
tion 0) with respect to the OGT catalytic domain X-ray
structure. As expected, we observed little relative movement
of the catalytic domain and UDP-GlcNAc moieties when
bound to five different peptide substrates: CK2, HCF-1PRO-
rep 2WT (Glu-10) and E10S mutant, and chimeric Ch13 and
Ch13-T14Y peptides.
As described previously (10), we observed significant TPR-
domain movements relative to the catalytic domain (Fig. 4D).
However, relative TPR-domain movements of OGT bound to
the two HCF-1 and chimeric Ch13 peptides were more con-
strained than those of the CK2 peptide. These results suggest
that peptides binding to both the catalytic domain and the TPR
domain restrict inter-TPR and catalytic domain movements.
The mutant Ch13-T14Y peptide-bound OGT displayed less
constrained inter-TPR and catalytic domain movements, simi-
lar to the CK2-bound OGT. These latter results are consistent
with an unstable TPR-Ch13-T14Y interaction observed in the
molecular dynamic simulations (data not shown) and the afore-
mentioned similar pattern of glycosylation between the Ch13-
T14Y and CK2 peptides (Figs. 2 and 3).
Fig. 4 (E and F) shows the relative movement of individual
backbone positions from 7 to 14 of the HCF-1PRO-repeat pep-
tides (position 10 being the glycosylation or cleavage position)
relative to the catalytic (E) and TPR (F) domains. The three
HCF-1 threonine-rich region–containing peptides behaved
nearly identically—relative to the catalytic domain, there was
little change in motion across the eight residues (Fig. 4E). Rel-
ative to the TPR domain, residues 7–10 exhibitedmoremotion
than residues 11–14, which are closer to the TPR domain (Fig.
4F). In contrast, the CK2 peptide residues displayed a bipartite
pattern relative to the catalytic domain, with the glycosylation
region residues 7–11 moving considerably less than the C-ter-
minal residues 12–14 (Fig. 4E), which are not anchored toOGT
via the TPR domain by the threonine-rich region. The same
decoupling of the CK2 peptide movements from the TPR
movements can be observed in Fig. 4F. These results are con-
sistent with the HCF-1PRO-repeat threonine-rich region serv-
ing to anchor peptides to OGT; such anchoring could explain
the relaxed co-substrate requirements of the HCF-1PRO-repeat
threonine-rich region–containing peptides.
UDP-5S-GlcNAc is active for HCF-1PRO-repeat threonine-rich
region containing peptide glycosylation
To probe further the effects of the threonine-rich region on
UDP-GlcNAc co-substrate requirements, we tested the gly-
cosylation substrate activities of the various peptides with
the previously described 5S-GlcNAc thio-derivative of
UDP-GlcNAc, a potent inhibitor of OGT glycosylation (6).
For these experiments, we compared by LC-MS the levels of
peptide glycosylation using the UDP-GlcNAc and
UDP-5S-GlcNAc co-substrates. Owing to the molecular dif-
ferences (hydrophobicity and molecular weight) of GlcNAc
Figure 5. UDP-5S-GlcNAc modification of HCF-1PRO-repeat threonine-rich region–containing peptides. CK2 (A), HCF-1PRO-repeat 2 E10S (B), Ch13 (C),
andCh13T(17–22)Apeptides (D)were incubatedwithWTOGTandeitherUDP-GlcNAc (blue) orUDP-5S-GlcNAc (red). Peptideglycosylationwasdetectedusing
LC-MS. The highest peak in each pair of samples was set at 100%. Single representative examples of three independent experiments are shown.
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and 5S-GlcNAc, the glycosylated peptides could be distin-
guished from one another in both the HPLC and MS steps of
the analysis, respectively.
As expected, the CK2 peptide was only glycosylated by the
UDP-GlcNAc co-substrate (Fig. 5A;m/z 662.661, blue). In con-
trast, the HCF-1PRO-repeat E10S peptide was effectively glyco-
sylated with both the UDP-GlcNAc (m/z 951.760, blue) and
UDP-5S-GlcNAc (m/z 957.085, red) co-substrates (Fig. 5B).
The fusion of the HCF-1PRO-repeat threonine-rich region to
the CK2 glycosylation region in a Ch13 peptide setting robustly
activated UDP-5S-GlcNAc modification of the CK2 sequence
(Fig. 5C, compare GlcNAc m/z 982.483 (blue) and 5S-GlcNAc
m/z 987.809 (red)), which depended on the conserved threo-
nine-rich region (Fig. 5D, m/z 942.469, blue). Thus, as for the
Rp-S-UDP-GlcNAc diastereomer, theHCF-1PRO-repeat thre-
onine-rich region relaxes the constraints on UDP-5S-GlcNAc
co-substrate utilization.
Activation of glutamate-directed cleavage in a heterologous
context by the HCF-1PRO-repeat threonine-rich region
The interaction of OGT with the HCF-1PRO repeat was first
elucidated in the context of its unexpected role in cleavage of
HCF-1 (1). Here, we have shown that the HCF-1PRO repeat and
in particular its threonine-rich region can activate unexpected
enzymatic OGT glycosylation activities in CK2-HCF-1PRO-re-
peat chimeras. In so doing, we observed, as shown in Fig. 4C,
that the structure of the CK2 glycosylation sequence in the
Ch13 chimera can adopt a very similar backbone structure to
the corresponding cleavage site and surrounding sequences of
the OGT-bound HCF-1PRO repeat. This led us to ask whether
simple replacement of the glycosylated CK2 serine residue by a
glutamate (i.e. S10E) might be sufficient to activate cleavage of
this non-HCF-1 sequence.
To answer this question, we first mutated the three-HCF-
1PRO repeat–containing HCF3R cleavage substrate into a sin-
gle-cleavage-site substrate by inactivating HCF-1PRO repeats 1
and 3, creating HCF3R-AEA (see Table S2 for sequences). We
then converted positions 3–13 of the central HCF-1PRO repeat
2 into the corresponding CK2 glycosylation site sequence—
creating a robust glycosylation substrate (called HCF3R-
A(CK2-S)A), as shown in Fig. S2—followed by mutation of the
single CK2 serine glycosylation acceptor into a glutamate resi-
due, thus creating HCF3R-A(CK2-E)A. Fig. 6 shows the results
of a cleavage assay with the HCF3R-AEA and HCF3R-A(CK2-
E)A substrates. As expected, the WT HCF-1PRO repeat in
HCF3R-AEA was effectively cleaved by WT OGT (compare
lanes 1 and 2) but not the inactivemutant K842M (lane 4) (2). A
previously described glycosylation-defective but proteolysis-
competent “Swap” mutant (D554H/H558D) (9) was, as ex-
pected, also active for cleavage (lane 3). The HCF3R-A(CK2-
E)A substrate was also effectively cleaved (compare lanes 5–8),
showing that OGT can cleave a substrate containing a gluta-
mate residue at the right position (position 10) in a non-HCF-1
sequence context. The elevated cleavage activity observed with
the OGT Swapmutant, in which residue Asp-554 is mutated, is
consistent with the results of Janetzko et al. (3).
HCF-1PRO-repeat threonine-rich region activates cleavage at a
properly positioned glutamate residue
In the aforementioned experiments, only two prominent ele-
ments of the HCF-1PRO repeat remained in the OGT proteoly-
sis substrate: the glutamate cleavage-site residue at position 10
and the threonine-rich region. To address the importance of
these two HCF-1PRO-repeat sequence elements for cleavage,
we turned to the peptide and LC-MS–based cleavage assay
recently described by Janetzko et al. (3), allowing us to simulta-
neously measure cleavage and glycosylation activities. An
essential feature of the Janetzko et al. (3) peptide-based LC-MS
cleavage assaywas the identification of an extendedHCF-1PRO-
repeat peptide substrate (called HCF-short; see Table 1) that is
efficiently cleaved byOGT intoN- andC-terminal fragments of
which the C-terminal fragment contains an N-terminal pyro-
glutamate cap (2, 3).
This HCF-short peptide was also effectively cleaved in our
assay as shown in Fig. 7A. The starting peptide (m/z 845.143,
top) essentially disappeared (bottom) after a 4-h incubation
with OGT. In its place appeared N-terminal (m/z 569.266,
green) and C-terminal pyroglutamate-capped (m/z 747.675,
red) fragments. (The differing intensities of the cleaved pep-
tides are probably owing to different detection efficiencies in
MS.) We also observed a peptide (m/z 895.912, blue) corre-
sponding to a monoglycosylated starting peptide; we did not
map the site of this glycosylation, but its sensitivity to the
Rp-S-UDP-GlcNAc diastereomer suggests that it is threonine,
as opposed to glutamate, glycosylation (data not shown).
Using the HCF-short peptide as a template, we synthesized
two CK2-HCF-1PRO chimera peptides analogous to those used
in Fig. 6 containing the CK2-Ser-10 glycosylation or CK2-
Glu-10 cleavage sequence linked to the threonine-rich region
of the HCF-1PRO repeat (called CK2(Ser-10)–Thr-rich and
CK2(Glu-10)–Thr-rich, respectively; see Table S1). As shown
in Fig. 7B, incubation of the CK2(Ser-10)–Thr-rich peptide
with OGT resulted in the disappearance of the starting peptide
Figure 6. Cleavage of chimeric glutamate modified CK2 sequence by
OGT. HCF3R-AEA (lanes 1–4) or chimeric HCF3R-A(CK2-E)A (lanes 5–8)
protein were incubated without (lanes 1 and 5) or with either WT OGT
(lanes 2 and 6) or OGT Swap (lanes 3 and 7) or K842M (lanes 4 and 8) mutant
OGTs. HCF3R protein cleavage was assayed by SDS-PAGE and immuno-
blotting using an anti-His antibody. Anti-OGT was used to detect levels of
OGT protein. Black rectangle, uncleaved HCF3R substrate; black circle,
cleaved product.
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(m/z 776.389) and conversion to a glycosylated peptide (m/z
827.167). Treatment of the CK2(Glu-10)–Thr-rich peptide
(m/z 786.897)withOGT led to a 50% loss of CK2(Glu-10)–Thr-
rich starting peptide (see the legend to Fig. 7). In its place, we
observed a pyroglutamate-capped C-terminal fragment (m/z
716.325) and minor monoglycosylated starting product (m/z
837.665). The CK2 N-terminal cleavage fragment, which con-
tains many hydrophilic residues, could not be detected. These
results indicate that the CK2(Glu-10)–Thr-rich peptide is
also a cleavage substrate of OGT but less effective than the
parental HCF-short peptide.
Using this cleavable CK2(Glu-10)–Thr-rich-peptide sub-
strate, we first asked whether the threonine-rich region is
important for cleavage activity by creating the CK2(Glu-10)–
Thr-rich peptide substrate as shown in Fig. 7D. Indeed, this
peptide (m/z 756.885/6) was not cleaved (nor glycosylated),
showing the key importance of the TPR-bound threonine-rich
region for activation of a glutamate-driven cleavage of a heter-
ologous sequence.
The cleavable CK2(Glu-10)–Thr-rich substrate contains a
C-terminal serine residue at position 11 (i.e. VE10S11), which is
largely ignored (Fig. 7D).We asked here how the position of the
glutamate (position 9 or 10) and serine (position 10 or 11) res-
idues with respect to the threonine-rich region can influence
the substrate cleavage and glycosylation activities of OGT. For
this purpose, we inserted an additional alanine residue in the
SAN linker sequence (changing the register with respect to the
threonine-rich region of the VE10S11A12N sequence into an
E9S10A11 A12N sequence; added alanine residue underlined),
effectively “pushing” the glutamate and serine at positions 10
and 11 away from theC-terminal threonine-rich region to posi-
tions 9 and 10, respectively. This substrate, calledCK2(E9S10)–
Thr-rich, was resistant to cleavage but was very effectively
glycosylated (Fig. 7E), showing the importance of the three-
amino acid linker region “register” between the TPR-bound
threonine-rich region for defining either glutamate-driven
cleavage or serine-driven glycosylation of an HCF-1PRO repeat–
related peptide substrate.
E10S glycosylation, but not Glu-10 cleavage, is inhibited by
combined disruption of the OGT enzyme and the UDP-GlcNAc
co-substrate
To date, two mechanisms of OGT-induced glycosylation,
which differ in how the serine/threonine acceptor site is depro-
tonated, have been described. (i) Schimpl et al. (5) propose
acceptor deprotonation by the UDP-GlcNAc -phosphate
pro-RP oxygen, an activity that would be inhibited by the
Rp-S-UDP-GlcNAc diastereomer, and (ii) Lazarus et al. (12)
propose a Grotthuss mechanism in which proton shuttling via
watermolecules occurs between the acceptor residue andOGT
residue Asp-554. In support of UDP-GlcNAc -phosphate
pro-RP oxygen deprotonation, the Rp-S-UDP-GlcNAc diaste-
reomer is indeed inactive for normal substrate glycosylation (5,
9), and, consistent with a Grotthuss mechanism, mutation of
theAsp-554 residue impairs normal substrate glycosylation (9).
Given the unexpected activity of the Rp-S-UDP-GlcNAc
diastereomer with the E10S HCF-1PRO repeat, we decided to
examine the activity of OGTmutants defective for normal sub-
strate glycosylation, in particular the Swap mutant mutated at
residue Asp-554 but active for proteolysis and the K842M
mutant defective for both glycosylation and proteolysis (see Fig.
6), on an E10SHCF-1PRO-repeat substrate, as shown in Fig. 8A.
Indeed, the otherwise glycosylation-defective OGT Swap
mutant (9) was readily active on the E10S HCF-1PRO-repeat
HCF3R-ASA substrate (compare lanes 2 and 3) and even dis-
played residual activity with the K842Mmutant (lane 4). Thus,
E10S glycosylation can occur with either the Rp-S-UDP-
GlcNAc diastereomer, bypassing the -phosphate pro-RP oxy-
gen deprotonation pathway, and with the Swapmutant bypass-
ing a Asp-554–promoted Grotthuss mechanism.
To determine whether the remaining activities in these two
different UDP-GlcNAc co-substrate and mutant OGT combi-
nations are completely independent, we tested glycosylation
activity in the presence of both theRp-S-UDP-GlcNAc diaste-
reomer and OGT Swap mutant as shown in Fig. 8B. Interest-
ingly, whereas when tested separately (lanes 2–6), they were
active on the E10SHCF3R-ASA substrate, when combined, the
Rp-S-UDP-GlcNAc diastereomer and OGT Swap mutant
Table 1
Summary of glycosylation and proteolysis activities of HCF-1PRO repeat–related and –unrelated substrates
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were inactive on the E10S HCF3R-ASA substrate (lane 7).
Thus, for glycosylation, the E10S HCF-1PRO-repeat substrate
independently bypasses a requirement for the -phosphate
pro-RP oxygen or for the Asp-554 residue implicated in the
proposed Grotthuss mechanism but not both in combination.
Similar to these E10S glycosylation results, we have previ-
ously shown that the Glu-10 HCF-1PRO-repeat proteolysis sub-
strate is active with either the Rp-S-UDP-GlcNAc diaste-
reomer co-substrate or the OGT Swap mutant, but we had not
tested them together for proteolysis (9). Fig. 8C shows such a
test. Interestingly, in contrast to the E10S serine glycosylation
substrate, the Glu-10 substrate is active for proteolysis in
the presence of both the Rp-S-UDP-GlcNAc diastereomer
co-substrate and the OGT Swap mutant (compare lanes 2–6
and 7). Such a result could be explained if proteolysis does not
require assisted deprotonation of the target glutamate for its
glycosylation and subsequent spontaneous backbone cleavage.
Discussion
This study reveals two unusual OGT enzymatic activities in
the context of the threonine-rich region of the HCF-1PRO
repeat: (i) enhanced serine glycosylation in the presence of
either otherwise inefficiently used UDP-GlcNAc co-substrates
or anOGTSwapmutant and (ii) glutamate-induced proteolysis
of a novel sequence otherwise unrelated to HCF-1. In the first
instance, high levels of serine glycosylation are achieved with
the Rp-S-UDP-GlcNAc diastereomer and UDP-5S-GlcNAc–
modified co-substrates or the otherwise inactive OGT Swap
mutant, and in the second instance, a heterologous CK2
sequence possessing an appropriately positioned glutamate
(Ser-to-Glu mutation) serves as a proteolytic substrate. Both
unusual activities depend on the HCF-1PRO-repeat region—a
region that anchors the protein substrate to the OGT TPR
domain for “presentation” to the OGT catalytic domain. Thus,
this study extends that of Kapuria et al. (9) in two important
ways; it shows that the HCF-1PRO-repeat region can (i) activate
unusual OGT serine glycosylation properties and not just pro-
teolytic properties and (ii) promote proteolytic cleavage at a
glutamate residue in a foreign cleavage-site context. Table 1
shows a summary of these unusual threonine-rich region–de-
pendent activities. Glycosylation of a canonical, nonthreonine-
rich region–containing substrate, represented here by CK2,
was, as expected (5, 9), sensitive to both inactivation of a
UDP-GlcNAc-phosphate pathway with Rp-S-UDP-GlcNAc
or an OGT-based mechanism with the OGT Swap mutant
potentially inactivating a Grotthuss mechanism. In sharp con-
trast, however, an HCF-1PRO-repeat threonine-rich region–
based substrate, here E10S, could circumvent inhibition of
either pathway separately but, strikingly, not together. Thus,
OGTand itsUDP-GlcNAc co-substrate can apparently use two
independent pathways for serine glycosylation, one enzyme-
based (a Grotthuss pathway) and the other co-substrate–based
(the -phosphate pathway). Although anMD simulation study
has suggested that an -phosphate–based mechanism is more
favorable than a Grotthuss-based mechanism (13), our study,
although showing that each can occur independently, does not
differentiate between the relative importance or favorability of
the two pathways. Indeed, with the canonical CK2 substrate,
where inhibition of either pathway inhibits glycosylation, the
two likely cooperate for serine/threonine glycosylation. This
multiplicity of OGT glycosylation strategies could represent
targets of alternate regulatory strategies.
As mentioned previously, the unusual OGT glycosylation
activities described here are dependent on the HCF-1PRO-re-
peat threonine-rich region.What is it about the threonine-rich
region that activates such unusual activities? The threonine-
rich region of the HCF-1PRO repeat is unusual in how it forms
an intimate association with the OGT TPR region (2) and pro-
motes stable association with OGT (1, 11). In contrast, it does
not seem to change how the site of glycosylation (or proteolysis)
is presented to the OGT catalytic domain and its bound
UDP-GlcNAc co-substrate. Thus, perhaps, it is the threonine-
rich region–based stabilization of substrates on OGT that is
providing sufficient conformational stability and/or time for
independent utilization of either -phosphate or Grotthuss
pathways, which otherwisemay be too inefficient for significant
levels of glycosylation. Consistent with a stabilization hypothe-
sis, the threonine-rich region also overcomes the low activity
observed with the UDP-5S-GlcNAc co-substrate.
Interestingly, the intimate interaction of the HCF-1PRO-re-
peat threonine-rich region with the OGT TPR domain can be
replaced by covalent fusion of an unrelated substrate toOGT at
the TPR domain. The resulting fusion generated an efficient
glycosylation substrate dependent on TPR domain interactions
but not a threonine-rich region (14).
Activation of proteolysis in a non-HCF-1PRO-repeat target
sequence
HCF-1PRO-repeat proteolysis is exquisitely dependent on the
HCF-1PRO-repeat threonine-rich region, yet it is remarkably
resistant to alterations in OGT or the UDP-GlcNAc co-sub-
strate that prevent both the proposed -phosphate and Grot-
thuss serine glycosylation pathways (Table 1). Apparently, glu-
tamate glycosylation,which is required for proteolysis (3), is not
dependent on these two pathways. Perhaps, it is simply the
stable association and proper positioning of the glutamate
residue adjacent to the UDP-GlcNAc co-substrate that are
prerequisites to HCF-1PRO-repeat glutamate glycosylation
and subsequent cleavage. Consistent with this is the proteo-
lytic activation shown here of a foreign sequence—the CK2
glycosylation sequence—for proteolysis.
Cleavage of the HCF-1PRO repeat by OGTwas a surprise (1).
To date, it is the only known natural proteolytic target of OGT.
Nevertheless, bymaking chimeric CK2/HCF-1PRO-repeat thre-
Figure 7. Cleavage of chimeric glutamate–modified CK2 sequence byOGT requires the threonine-rich region and glutamate residue on position 10.
A–E, LC-MS analysis of WT OGT cleavage of the HCF-short (A), CK2 (Ser-10)–Thr-rich (B), CK2 (Glu-10)–Thr-rich (C), CK2 (Glu-10)–Thr-rich (D), and CK2
(E9S10)–Thr-rich (E) peptides at 0 and 4 h. Native (black) and glycosylated (blue) full-length peptides and cleaved N-terminal pyroglutamate-modified (red)
andC-terminal (green) fragments are shown. The y axis in all plots is set at 100% for the tallest peak. InC, for the CK2 (Glu-10)–Thr-richpeptide, the tallest peak
at the 4 h time point is50% of the abundance level as comparedwith the 0 h time point. Single representative examples of three independent experiments
are shown.
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onine-rich region peptides and simply converting the CK2 ser-
ine acceptor into a glutamate, we generated a sequence unre-
lated to the HCF-1PRO-repeat cleavage site that is cleaved by
OGT.The position of the glutamate residue relative to the thre-
onine-rich region was nevertheless critical. Thus, any other
proteolytic targets ofOGTwould likely need to consist of a TPR
domain–binding site with HCF-1PRO-repeat threonine-rich
region properties followed by an appropriately positioned glu-
tamate residue. Such other natural sites remain to be found.
Experimental procedures
Reagents and peptides
UDP-GlcNAc (U4375) was obtained from Sigma, whereas
thio-analogues of UDP-GlcNAc (UDP-5S-GlcNAc, Sp-S-
UDP-GlcNAc, and Rp-S-UDP-GlcNAc) were synthesized as
described (5). Calf alkaline phosphatase was obtained from
New England Biolabs. Peptides (Table S1) were obtained from
Biomatik. Anti-OGT (sc-32921) and anti-CK2 (sc-12738)
antibodies were purchased from Santa Cruz Biotechnology,
Inc. (Dallas, TX), and anti-O-GlcNAc (RL2) antibody was pur-
chased from Abcam (Cambridge, UK). Ni-NTA superflow and
DTT were purchased from Sigma-Aldrich, and lysozyme was
purchased from Roche Applied Science.
HCF3R-vector construct preparation
cDNA sequences coding for HCF3R-ASA, -AEA, -A(CK2-
E)A, and -A(CK2-S)A were synthesized by Eurofins MWG
Operon (Ebersberg, Germany) and inserted into the pET47b
vector digested with BamHI and NotI as described previously
(9). The amino acid sequences are provided in Table S2. The
fusion proteins contained a His8 tag at their N termini.
Protein purification of OGT and HCF3R substrates
WT and mutant OGT and the AEA, ASA, A(CK2-E)A, and
A(CK2-S)A HCF3R constructs were purified from Escherichia
coliBL21(DE3) cells byNi-NTA affinity as described previously
(9). To concentrate and desalt theNi-NTAeluate, Amicon con-
centration tubes (Millipore) were used (Ultra 3K for HCF3R,
Ultra 10K forOGT) as per themanufacturer’s instructions. The
concentrated proteins were supplemented with 1mMDTT and
stored at80 °C.
Protein glycosylation assays
CK2 (2500 units; New England Biolabs) was incubated with
OGT (WT; 500 nM) in 15 l of TBS buffer supplemented with
0.1 mM UPD-GlcNAc, Sp-S-UDP-GlcNAc, or Rp-S-UDP-
GlcNAc and 1 mM DTT at 37 °C for 60 min. The reaction was
ended by the addition of 2 Laemmli buffer and boiling the
sample. Anti-O-GlcNAc was used to assess the glycosylation of
CK2, whereas anti-CK2 and anti-OGTwere used to detect total
CK2 and OGT protein levels, respectively. Similar assays was
performed to probeHCF3R-ASA andHCF3R-A(CK2-S)A pro-
tein glycosylation using 25 M substrate protein concentration
and 0.5 M OGT (WT, Swap, K842M) . Anti-His tag antibody
was used to detect total levels of HCF3R substrate proteins.
Peptide glycosylation assays for LC-MS analyses
Peptide glycosylation assays were performed using 10 M
peptide, 25 M UDP-GlcNAc, or thio-analogues of UDP-
GlcNAc and 0.2MOGT in 20l of TBSbuffer (50mMTris, pH
7.4, 150mMNaCl) supplementedwith 1mMDTT and calf alka-
line phosphatase (0.1 unit/l). The reaction was terminated
after 1 h by the addition of 20 l of cold methanol.
Protein cleavage assays
The HCF3R-AEA and - A(CK2-E)A cleavage assay was per-
formed by mixing 25 M HCF3R substrate with 1.0 M OGT
(WT, Swap, K842M) in 30 l of TBS buffer supplemented with
0.1 unit/l calf alkaline phosphatase, 1 mM UPD-GlcNAc
(unless otherwise noted), and 1 mM DTT for 6 h at 37 °C. The
reaction was ended by the addition of 2 Laemmli buffer and
sample boiling. Anti-His antibody was used to detect cleavage
of HCF3R proteins.
Peptide cleavage assays for LC-MS analyses
Peptide cleavage assays were performed as described before
(3) with slight modifications. Typical cleavage assay mixture
contained 5M substrate peptide in 20l of TBS buffer supple-
mented with 0.1 units/l calf alkaline phosphatase, 5 mMDTT,
and 1 mM UDP-GlcNAc. Enzyme OGT (5 M) was added last,
and reactions were either terminated immediately (0 h time
point) or after 4 h of incubation at 37 °C in a thermomixer, by
the addition of 20 l of cold methanol supplemented with 0.1%
formic acid.
LC-MS analyses
Peptide samples were diluted in a loading buffer (98:2 H2O/
acetonitrile  0.05% TFA) and injected on an Ultimate RSLC
3000 nanoHPLC system (Dionex, Sunnyvale, CA) interfaced to
a high-resolution mass spectrometer, QExactive Plus (Thermo
Fisher, Bremen, Germany). Peptides were loaded onto a trap-
ping microcolumn, Acclaim PepMap100 C18 (20 mm 
100-m inner diameter, 5 m; Dionex) before elution on an
Easy Spray C18 PepMap column (50 cm 75-m inner diam-
eter, 2 m, 100 Å; Dionex) at a flow rate of 0.25 l/min. A
gradient from4 to 76% acetonitrile in 0.1% formic acidwas used
for peptide separation (total time, 65min). FullMS survey scans
were performed with resolution of 70,000. In data-dependent
acquisition controlled by Xcalibur version 4.0 software, the 10
most intensemultiple-charge precursor ions detected in the full
MS survey scan were selected for higher-energy collision-in-
duced dissociation (HCD, normalized collision energy 27%)
Figure 8. OGT Swap mutant displays Rp-S-UDP-GlcNAc diastereomer co-substrate sensitivity for E10S glycosylation. A, in vitro glycosylation of
HCF3R-ASA substrate was assayed using either no OGT (lane 1) or WT (lane 2) or mutant Swap (lane 3) or K842M (lane 4) OGT. Substrate glycosylation was
detected using RL2 anti-O-GlcNAc antibody. HCF3R-ASA protein (IB) was detected with anti-His antibody. B, in vitro glycosylation of HCF3R-ASA was assayed
using either no OGT (lane 1) or WT or SwapOGTwith 0.5mMUDP-GlcNAc (lanes 2 and 3), Sp-S-UDP-GlcNAc (lanes 4 and 5), or Rp-S-UDP-GlcNAc (lanes 6 and
7). Substrate glycosylation was detected using RL2 anti-O-GlcNAc antibody. Anti-His antibody (IB) was used to detect the HCF3R-ASA protein. C, in vitro
cleavage assay of HCF3R-AEA. The assay conditions are as in B. Anti-His antibody was used to detect uncleaved and cleaved HCF3R-ASA proteins. Black
rectangle, uncleaved HCF3R substrate; black circle, cleaved product.
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and analysis in the Orbitrap at 17,500 resolution. An isolation
window of 1.5 m/z units around the precursor was used, and
selected ions were then dynamically excluded from further
analysis for 60 s.
For a more accurate localization of the O-GlcNAcylation on
the E10S peptide, some samples were further analyzed with
targeted electron transfer dissociation (with HCD supplemen-
tal activation) (EThcD) MS/MS fragmentation on an Orbitrap
Fusion Tribrid mass spectrometer (Thermo Fisher Scientific,
Bremen, Germany) interfaced via a nanospray source to a
Dionex RSLC 3000 nanoHPLC system (Dionex, Sunnyvale,
CA). After loading, peptides were separated on a custom-
packed nanocolumn (75-m inner diameter  40 cm, 1.8-m
particles, Reprosil Pur, Dr. Maisch) with a gradient from 4 to
76% acetonitrile in 0.1% formic acid at a flow rate of 0.25l/min
in 65 min. Targeted MS/MS of the 4 charged state of the
O-GlcNAcylated E10S peptide (m/z 714.072) was performed at
15,000 resolution, using EThcD fragmentation, with a 100-ms
reaction time (electron transfer dissociation) and a supplemen-
tal activation energy at 25% (HCD).
MS data processing
On the one hand, LC-MS/MS files were analyzed manually
with Xcalibur software to extract m/z intensities of expected
peptides, and on the other hand,MS/MS spectra were searched
using Mascot version 2.6 software (Matrix Science, London,
UK) to confirm identifications with a custom database contain-
ing the peptide sequences.
Mascot searches were carried out with a parent ion tolerance
of 10 ppm and a fragment ion mass tolerance of 0.02 Da, with-
out any enzyme cleavage. Oxidation of methionine and
N-acetylhexosaminemodification of serine and threonine were
specified as variable modifications. Additional peptide C-ter-
minal amidation and cysteine dehydro (half of a disulfide
bridge) modification were also considered, depending on the
sequence of the analyzed peptides. In cleavage assays, forma-
tion of pyroglutamic acid from N-terminal glutamic acid was
also specified as a variable modification in Mascot searches.
Immunoblotting
Proteins were resolved using SDS-polyacrylamide gels and
blotted onto nitrocellulose membranes. The following primary
antibodies were used at the following dilutions: anti-O-GlcNAc
RL2 (1:1000), anti-OGT (1:5000), and anti-CK2 (1:1000).
IRDye 680 donkey anti-rabbit and IRDye 800 donkey anti-
mouse were used at dilutions of 1:10,000. Blots were imaged
using the LI-COR Odyssey IR imaging system (LI-COR, Lin-
coln, NE).
Molecular dynamics simulations
Periodic-boundary MD simulations were carried out with
GROMACS version 2016.4 (15, 16), using the all-atom
CHARMM27 force field (17, 18) and the TIP3P water model
(19). Electrostatic interactions were calculated with the Ewald
particle-mesh method (20) with a grid spacing of 1.2 Å and a
spline interpolation of order 4. A cut-off of 10 Åwas applied for
the real-space direct sum part of the Ewald sum and also for the
van der Waals interactions. Dispersion corrections were
applied to the energy. Bonds involving hydrogen atoms were
constrained using the P-LINCS algorithm (16). The systemwas
coupled to a Berendsen barostat with a relaxation time of 1 ps.
The solute and the solvent were separately coupled to two ther-
mostats (21), each with a relaxation time of 0.2 ps. The time
integration step was set to 2 fs, the temperature to 300 K, and
the pressure to 1 bar. A cubic simulation cell with an edge
length of 120Åwas used to prevent direct interactions between
periodic images, resulting in about 170,000 atoms per system.
Sodium atoms were added to neutralize each system. Initial
structureswere optimized, heated from0 to 300K over a period
of 0.1 ns, equilibrated for a further 0.9 ns restraining each solute
nonhydrogen atom to its original position, and finally equili-
brated for 0.5 ns without restraints before data collection. For
each system, eight simulationswere carried out for a total of 200
ns of production time, saving coordinates every 0.05 ns. For
analysis, structural snapshots were superimposed either based
on the backbone of the OGT catalytic domain (residues 467–
1028) or of the TPR domain (residues 312–466) before calcu-
lating backbone RMSDs from the respective X-ray structure.
Five different systemswere simulated:OGTwithHCF-1PRO-
repeatGlu-10 andE10S,OGTwithCK2peptide, andOGTwith
chimeric peptides Ch13 and Ch13-T14Y. Simulations in com-
plex with HCF-1–derived peptides were based on the X-ray
structure 4N3B (2), replacing UDP-5S-GlcNAc with UDP-GlcNAc
and Gln-10 with Glu or Ser. Simulations in complex with the
CK2 peptide were based on the X-ray structure 4GYY (12),
replacing UDP-5S-GlcNAc with UDP-GlcNAc. Simulations in
complex with chimeric peptides were based on the homology
model (see below).
Homologymodel for chimeric Ch13 peptide
The model of the Ch13 peptide in complex with OGT was
obtained using the Modeler program (22, 23), version 9. Tem-
plate experimental structures (i.e. PDB entries 3PE4 (10), 4GYY
(12), 4N39 (2), 4N3A (2), 4N3B (2), and 4N3C (2)) were taken
from the Protein Data Bank (24). 500 models were produced
and ranked according to the modeler objective function. The
model with the best modeler objective function score was
retained for analysis.
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